Neuroendocrine carcinoma metastatic

5 trials 2 recruiting MedDRA PT
5 Registered trials
2 Recruiting
4 Unique sponsors
7 Unique IMPs
0 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 2
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Monoclonal antibody (immune) 2 substances
Checkpoint inhibitor (PD-L1) 1 substance
Phase II: 5 Phase I: 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase II

5 trials
  • G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica Academic
    DURVALUMAB
    2024-516157-41-00 1 country 2022 n=49
    Ended
  • Hospices Civils De Lyon Academic
    DOMVANALIMAB; ZIMBERELIMAB
    2024-519922-19-00 1 country n=77
    Not authorised
  • Rigshospitalet Academic
    FLUDEOXYGLUCOSE (18F); PYRUVIC ACID
    2024-516131-28-00 1 country 2022 n=15
    Recruiting
  • Rigshospitalet Academic
    DOTATATE, COPPER (64CU) CHLORIDE; FLUDEOXYGLUCOSE (18F)
    2024-516156-18-00 1 country 2023 n=200
    Recruiting
  • G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica Academic
    DURVALUMAB
    2024-516157-41-00 1 country 2022 n=49
    Ended

Phase I

1 trial
  • Uppsala University Academic
    HUMAN ADENOVIRUS C SEROTYPE 5 WITH E1 GENE CONTROLLED BY CHROMOGRANIN A PROMOTER AND HEXON MODIFIED WITH PROTEIN TRANSDUCTION DOMAIN MOTIF
    2024-517654-10-00 1 country 2016 n=20
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica Academic 2 Phase II 0
Rigshospitalet Academic 2 Phase II 2
Uppsala University Academic 1 Phase I 0
Hospices Civils De Lyon Academic 1 Phase II 0
New trials by year
2022
3
2023
1
← All indication landscapes